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Abstract
Pulmonary embolism management has typically been accomplished with 
anticoagulant treatment that includes parenteral heparins and oral vitamin K 
antagonists. Even though heparins and oral vitamin K antagonists continue to 
play a role in pulmonary embolism management, other newer available options 
have somewhat reduced the role of heparins and vitamin K antagonists in 
pulmonary embolism management. This reduction in utilization involves their 
toxicity profile, clearance limitations, and many drug and nutrient interactions. 
New direct oral anticoagulation therapies have led to more available options in 
the management of pulmonary embolism in the inpatient and outpatient set-
tings. More evidence and research are now available about reversal agents and 
monitoring parameters regarding these newer agents, leading to more interest 
in administering them for safe and effective pulmonary embolism management. 
Current research and literature have also helped direct the selection of appropri-
ate use of pharmacological management of pulmonary embolism based on the 
specific population such as patients with liver failure, renal failure, malignancy, 
and COVID-19.
Keywords: pulmonary embolism (PE), venous thromboembolism (VTE), 
anticoagulants, direct oral anticoagulants (DOAC), heparin,  
vitamin K antagonist (VKA)
1. Introduction
Pulmonary embolism (PE) is a type of venous thromboembolism (VTE) that 
is potentially fatal but can be treated with different types of therapy. PE is an 
obstruction of the pulmonary arteries that can be caused by a clot, tumor, fat, or 
air. PE occurs when a portion of a blood clot breaks off and travels until it lodges 
in the pulmonary arteries [1]. Most deep vein thrombosis will develop in the lower 
extremities, but up to half can lead to PE [2]. PE is a significant health issue in the 
US, since there is an increased prevalence of this condition in the elderly. Other risk 
factors include obesity, heart failure, and cancer [3].
Current anticoagulation management guidelines prefer direct oral anticoagu-
lants (DOAC) such as dabigatran, rivaroxaban, apixaban, and edoxaban for initial 
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and long-term therapy for treating PE [4]. DOACs are preferred over vitamin K 
antagonist (VKA) therapy. This is due to the similar risk reduction for recurrent 
VTE, reduced risk of bleeding, and improved patient and provider convenience 
over the intensive monitoring associated with VKA therapy [4]. Each of the DOACs 
has demonstrated similar efficacy outcomes compared to VKA therapy with recur-
rent embolism [4]. In contrast, the risk of bleeding differs with the DOACs, which 
demonstrate less risk when compared to warfarin [4]. One possible exception to 
this, however, is that gastrointestinal bleeding may be higher with dabigatran, riva-
roxaban, and edoxaban compared to warfarin. This has been observed in patients 
treated with atrial fibrillation [4]. Treatment recommendations differ when man-
aging PE in special populations such as cancer, pregnancy, obesity, elderly, renal 
dysfunction, hepatic dysfunction, and COVID-19. Low-molecular-weight heparin 
(LMWH) is recommended over VKA therapy in cancer-associated thrombosis. 
Evidence suggests that LMWH is more effective in reducing recurrent embolism in 
this population and is more reliable in patients who have difficulty tolerating oral 
intake. It further removed the need for frequent monitoring of the international 
normalized ratio (INR) [4]. The prevention of PE in hospitalized patients includes 
either LMWH, low-dose unfractionated heparin (UFH) administered twice or three 
times daily, or fondaparinux [5]. Bleeding remains a concern with anticoagula-
tion therapy. With the availability of reversal agents, clinicians have been able to 
push the boundaries of PE management with confidence in both the inpatient and 
outpatient settings.
The duration of anticoagulant therapy for PE is 3 months, at minimum, which 
may be extended or indefinite in selected circumstances [4]. In patients with a 
PE provoked by surgery or a nonsurgical transient risk factor, the recommended 
duration of anticoagulation is 3 months [4]. In patients with an unprovoked PE, 
bleeding risk determines the duration, but in patients with high bleeding risk, the 
duration remains at 3 months. In low to moderate bleeding risk, the duration of 
therapy becomes indefinite [4].
2. Unfractionated heparin (UFH)
UFH is a parenteral anticoagulant that works by inactivating thrombin (IIa) 
and factor Xa via antithrombin. It is derived from porcine or bovine tissue. UFH 
is the anticoagulant of choice in patients with PE who have a high bleeding risk, 
critical illness, or need a surgical/invasive procedure. This is due to its short half-
life that ranges from 0.5 to 1.5 h, leading to the anticoagulant effect’s rapid onset 
and offset within hours of IV discontinuation [6]. Furthermore, due to its unique 
metabolism and clearance through the reticuloendothelial system, it is a desirable 
option for patients with poor and/or unstable renal function (creatinine clearance 
(CrCL) < 30 mL/min) [1]. Lastly, UFH lacks cytochrome P450 enzyme activity 
in the liver, and hence, drug interactions are predominantly limited to increased 
bleeding risk with concurrent anticoagulant and antiplatelet therapy. This makes it 
a favorable agent in patients with concerns of drug–drug interactions [7].
The IV route is the preferred mode of administration in shock and/or hypoten-
sion due to the absorption variability from subcutaneous tissues secondary to 
UFH plasma protein binding [6]. Dosing and special considerations for UFH are 
discussed in Table 1.
Some adverse drug reactions of concern are thrombocytopenia and major 
bleeding, such as intracranial and gastrointestinal bleeds. Heparin-associated 
thrombocytopenia can present in two forms. There is an early, benign, reversible 
nonimmune thrombocytopenia form and a late, more serious immunoglobulin G 
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(IgG)-mediated immune thrombocytopenia type, referred to as heparin-induced 
thrombocytopenia (HIT). HIT poses a concern with UFH use in the treatment 
of PE, with the overall incidence being reported to be up to 7% in patients with 
a mortality of 20–30% and varies depending on factors such as patient popula-
tion (surgical vs. medicine), duration of heparin use, and the type of heparin 
administered [8, 9]. UFH has a threefold higher risk of HIT compared to LMWH 
and serious limb-threatening and life-threatening complications [10]. The 
mechanism of HIT stems from IgG formation against the heparin/PF4 complex 
on platelets. Once IgG binds to the heparin/PF4 complex on platelets, the platelets 
become activated, resulting in venous and arterial thrombi formation [10, 11]. 
Monitoring platelets every 2–4 days or more frequently in higher-risk patients is 
recommended in patients on treatment doses of heparin [11]. Another side effect 
of concern is the significant reduction in bone density reported in about 30% of 
adult patients and the symptomatic bone fractures that occur in 2–3% of adult 
patients receiving heparin for at least 1 month or more [12].
A complete outline of first line and alternate reversal agents utilized for antico-
agulants for PE management is outlined in Table 2. Protamine sulfate is a reversal 
agent indicated for the reversal of UFH- and LMWH-associated bleeds. This agent 
is administered by a slow IV infusion at doses <5 mg/min due to the concerns of 
anaphylaxis, hypotension, bradycardia, and respiratory toxicity associated with the 
rapid infusion [13]. Due to UFH’s short half-life, a reversal agent may not be neces-
sary for most cases, as the UFH effect will normalize due to its rapid clearance [13].
Drug Dose Special considerations
UFH 1 80 unit/kg IV bolus, followed by an 
18-unit/kg/h infusion [6].
Enoxaparin 1 mg/kg subQ 2 BID 3 [13, 14].
Dalteparin 200 IU/kg/day 4 subQ for one month, 
followed by 150 IU/kg/day subcutaneously 
for months 2 through 6 [15].
Maximum of 18,000 IU per day.
Fondaparinux <50 kg:5 mg subQ daily
50–100 mg: 7.5 mg subQ daily
>100 kg: 10 mg subQ daily
Initiate warfarin within 72 h and give 
concomitantly for at least 5 days.
Edoxaban 60 mg po once daily; 30 mg once daily if 
body weight ≤ 60 kg
Not for use in patients with CrCl 
>95 mL/min 5.
Dose after 5 to 10 days of initial therapy 
with a parenteral anticoagulant.
Apixaban 10 mg po twice daily for 7 days followed 
by 5 mg twice daily [16].
Rivaroxaban 15 mg po twice daily x 3 weeks, then 
20 mg once daily x at least 6 months [17].
Take with food to improve absorption 
[18–20]
Dabigatran 150 mg po BID [34].; 110 mg BID for 
patients ≥80 years
Dose after 5 to 10 days of initial therapy 
with a parenteral anticoagulant.
Reduce dose to 110 mg BID for patients 
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3. Low-molecular-weight heparins (LMWH)
LMWHs, including enoxaparin and dalteparin, are defined as having a mean 
molecular weight that is less than 50% of that of UFH. They offer the advantage of 
consistent anticoagulant effect administered subcutaneously and dosing by body 
weight. Dosing and special considerations for LMWH (enoxaparin and dalteparin) 
are discussed in Table 1. LMWH is currently the preferred anticoagulant for active 
malignancy and pregnancy. However, newer study findings support the notion that 
DOACs may benefit VTE treatment in cancer patients [14].
Thrombocytopenia and major bleeding are also possible adverse effects of 
concern. While the risk of HIT is lower with LMWH in comparison with UFH, 
a baseline platelet count is suggested as a basis from which to contemplate the 
development of HIT. Further treatment with LMWH should be avoided in patients 
with a known history of HIT. Although it less likely to trigger the formation of HIT 
antibodies than UFH, LMWHs are just as effective as UFH in triggering platelet 
activation by HIT antibodies [12].
Routine anti-Xa monitoring is generally not recommended for enoxaparin 
but can be considered in patients with severe or unstable renal function and 
obese patients with a BMI ≥ 40 kg/m2 (or > 190 kg) who will be on enoxaparin 
for longer than 1 to 2 weeks [13, 14]. The anti-Xa level peak is drawn 4 h after the 
enoxaparin dose is administered when a steady state is achieved with a target range 
of 0.6–1.0 IU/mL [14, 21]. Monitoring anti-Xa activity in morbidly obese patients 
>120–140 kg and patients with severe or unstable renal function may be considered 
for dalteparin with a target anti-Xa range of 0.5–1.5 IU/mL [15]. Similar to enoxa-
parin, the anti-Xa levels in patients taking dalteparin must be drawn 4–6 h after 
the dalteparin dose is administered and once a steady state is achieved (receiving at 
least 3 to 4 doses) [15].
LMWHs are only partially reversed by protamine (60 to 80%), since binding 
only occurs with long, large-molecular-weight heparin proteins [13]. Due to its 
small size, fondaparinux is not reversed by protamine [13]. Protamine is known to 
interact with platelets, fibrinogen, and other plasma proteins. This may result in an 
First-line reversal agent Alternative reversal agents
UFH 1 Protamine sulfate
LMWH 2 Protamine sulfate
VKA 3 4F-PCC 4 FFP 5
Dabigatran Idarucizumab PCC 6
aPCC 7
Direct oral factor-Xa inhibitors Andexanet alfa PCC
aPCC
Fondaparinux Factor VIIa aPCC
Andexanet alfa
1UFH: Unfractionated heparin.
2LMWH: low molecular weight heparin.
3VKA: vitamin K antagonist.
44F-PCC: 4-factor prothrombin complex concentrate.
5FFP: fresh-frozen plasma.
6PCC: prothrombin complex concentrate.
7aPCC: activated prothrombin complex concentrate.
Table 2. 
Recommended reversal agents for anticoagulant therapy.
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anticoagulant effect of its own; thus, the minimal amount of protamine required to 
neutralize heparin present in the plasma should be administered [13].
4. Vitamin K antagonist (VKA)
VKA such as warfarin is a vitamin K receptor antagonist that continues to play 
a role in PE treatment, particularly in patients with severe renal insufficiency, 
antiphospholipid syndrome, and financial constraints who are unable to afford 
DOACs [22]. International normalized ratio (INR) monitoring is recommended 
for warfarin monitoring [23]. Due to the drug’s long half-life, slow depletion of 
factor II, and rapid depletion of anticoagulant protein C, patients are bridged with 
UFH, LMWH, or fondaparinux for at least 5 days and until the INR reaches the 
 therapeutic range of 2 to 3. [24].
Frequent monitoring may be a barrier to initiating this agent. Furthermore, 
several food and drug interactions may also limit the desire to initiate warfarin for 
long-term therapy. Food that is high in vitamin K content such as oils, fats, liver, 
nuts, and green vegetables may decrease the efficacy of warfarin. Medications 
that are inducers and inhibitors of CYP2C9, 2C19, 1A2, and 3A4 must require dose 
adjustments and/or more frequent monitoring of their INR. For these reasons, 
patients are educated about maintaining consistency with their vitamin K intake 
and encouraged to discuss any dietary or medication changes with their healthcare 
provider [25].
Vitamin K is recommended for warfarin reversal if the INR is >10 without 
significant bleeding and with repeated vitamin K doses every 6–24 h as needed 
[55]. Vitamin K can be administered by IV or the oral route, with a preference for 
oral administration; there is an associated risk of anaphylactoid reactions in 3 out 
of 10,000 patients when IV formulations were administered [56]. Subcutaneous 
injection is not recommended due to a delayed and unpredictable effect [55]. The 
availability of 4F-PCC (KCentra®) during the last decade has resulted in its use 
over FFP as a reversal agent for warfarin-associated bleeding complications. This 
agent has been employed especially for life-threatening bleeding, where 4F-PCC 
has demonstrated 25 times more potency in replacing vitamin K-dependent clotting 
factors than FFP [53]. The limitations of FFP in comparison with 4F-PCC include 
its slower onset, risks of allergic reaction and infection transmission, blood group 
compatibility, longer preparation time, and higher volume [53]. A major advantage 
of 4F-PCCs is their ability to be stored at room temperature as a lyophilized powder 
and the fact that they can quickly be reconstituted and administered [53]. With 
life-threatening bleeding, the addition of vitamin K 5 to 10 mg by slow IV infusion 
is suggested [57].
5. Factor Xa inhibitor injectable
Fondaparinux (Arixtra®) is a synthetic pentasaccharide anticoagulant selec-
tively inhibiting factor Xa via antithrombin-dependent actions with no inhibition 
of thrombin (factor IIa) [26]. Unlike LMWH and UFH, fondaparinux inhibits a 
targeted step in the coagulation cascade that leads to its anticoagulant effect [26]. 
Fondaparinux is currently approved in the United States for the treatment of PE in 
conjunction with warfarin [26]. Dosing and special considerations for fondaparinux 
are discussed in Table 1.
The most common adverse reaction associated with the use of fondaparinux is 
bleeding complications. While most other agents used for PE management do have a 
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reversal agent, this medication does not. Fondaparinux does not require laboratory 
monitoring. However, periodic complete blood count, serum creatinine level, stool 
occult tests, and anti-Xa level can be monitored on an individual basis [26].
For fondaparinux, recombinant activated factor VII and aPCC have some data in 
human and animal studies, respectively, as reversal agents. Both andexanet alfa (a 
recombinant factor Xa) and aripazine have been shown to bind to Xa inhibitors but 
lack any human data with fondaparinux [54].
6. Direct oral anticoagulant (DOACs)
6.1 Apixaban
Apixaban is an oral direct factor Xa inhibitor approved for the treatment and 
prevention of DVT and PE [16]. Dosing and special considerations for apixaban use 
for PE treatment are discussed in Table 1. The oral bioavailability is approximately 
50%, with most of the drug absorption occurring in the small intestine [29]. Drug 
elimination occurring via the metabolism through the CYP3A4 systems in the intes-
tine and liver and the P-glycoprotein system can be enhanced through drug–drug 
interactions [22, 25–29]. Once absorbed, the terminal half-life ranges between 8 and 
12 h, with a steady state achieved within 3 days [22, 25–29]. The premature discon-
tinuation of any anticoagulant, including apixaban, increases the risk of thrombotic 
events and is listed as a black box warning [16]. Epidural or spinal hematomas may 
occur in patients treated with apixaban in neuraxial anesthesia or spinal puncture. 
These hematomas have long-term consequences, such as permanent paralysis. Such 
risks should be taken into account when patients on apixaban therapy are scheduled 
for spinal procedures [16].
Andexanet alfa (Andexxa®) can be used to reverse apixaban (off-label) in life-
threatening or uncontrollable bleeding. The dosing is based on the specific factor 
Xa agent-inhibitor to be reversed, dose, and the time since the last dose was admin-
istered [58]. Andexanet alfa 400 mg intravenous bolus is administered at a rate of 
30 mg/min, followed by 4 mg/min via continuous infusion for up to 120 min, to 
reverse apixaban (5 mg or less) or rivaroxaban (10 mg or less), administered within 
8 h or if the time is unknown [58]. High-dose andexanet alfa is also indicated for 
apixaban doses of greater than 5 mg, or, if unknown, administered within 8 h or 
an unknown time. The high-dose andexanet alfa regimen is 800 mg intravenous 
bolus at a target rate of 30 mg/min, followed by 8 mg/min continuous infusion for 
up to 120 min [58]. The safety and efficacy of administering more than one dose 
of any of these regimens have not been established [58]. In the absence of either 
idarucizumab or andexanet alfa for DOAC reversal, administering prothrombin 
complex concentrate (PCC) or activated prothrombin complex concentrate (aPCC) 
is alternative to consider. This is based on the limited available human and animal in 
vitro studies [53]. Activated charcoal for the known recent ingestion of DOACs may 
also be effective when DOAC ingestion occurs within the last 2–4 h [53].
6.2 Rivaroxaban
Rivaroxaban is an oral direct factor Xa inhibitor approved for the prevention 
and treatment of DVT and PE. Dosing and special considerations for rivaroxaban 
use for PE treatment are discussed in Table 1. The oral bioavailability ranges from 
approximately 80 to 100% for a 10 mg dose and up to 66% for a 20 mg [31–33]. 
Bioavailability of doses ≥15 mg is improved with food [31–33]. Renal elimination 
accounts for approximately 36% of unchanged drug, its use in patients with a 
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CrCL <30 mL/min is not advised, and <15 mL/min employment is contraindicated 
[31–33]. Rivaroxaban is not dialyzable [31–33]. Rivaroxaban follows a similar 
elimination pattern to that of apixaban, with metabolism through the CYP3A4 
systems accounting for 57% elimination [31–33]. P-glycoprotein system inhibitors 
may lead to elevated rivaroxaban serum levels [28–30]. Rivaroxaban’s terminal half-
life ranges between 5 and 9 h, with a prolonged half-life of 11–13 h seen in elderly 
patients [31–33]. The steady-state concentrations for this agent tend to occur within 
3 days. The premature discontinuation of any anticoagulant, including rivaroxaban, 
increases the risk of thrombotic events and is listed as a black box warning [17]. To 
minimize this risk, an alternate coverage should be considered, should rivaroxaban 
be discontinued for a reason apart from pathological bleeding or therapy comple-
tion [17]. Epidural or spinal hematomas have been observed in patients managed 
with rivaroxaban undergoing neuraxial anesthesia or spinal puncture. Such hema-
tomas are known to result in long-term or permanent paralysis [17].
Andexanet alfa (Andexxa®) can also be used to reverse rivaroxaban (off-label) 
in life-threatening or uncontrollable bleeding. Rivaroxaban doses of greater than 
10 mg, or if an unknown amount is administered within 8 h or at an unknown time, 
are managed with the high-dose andexanet alfa regimen [58].
6.3 Dabigatran
Dabigatran (Pradaxa®) is a direct thrombin (IIa) inhibitor approved for the pre-
vention and treatment of DVT and PE. Dosing and special considerations for dabi-
gatran use for PE treatment are discussed in Table 1. Dabigatran should be initiated 
0–2 h before the next dose of parenteral anticoagulant would have been due, or at 
the time of discontinuation of UFH continuous infusion [34]. The medication has 
low oral bioavailability and undergoes hepatic metabolism. P-glycoprotein (P-gp) 
inducers, such as phenobarbital, rifampin, and fosphenytoin, reduce exposure to 
dabigatran and should be avoided [34]. In contrast, P-glycoprotein (P-gp) inhibi-
tors increase exposure to dabigatran, and recommendations vary based on the P-gp 
inhibitor and the indication for dabigatran use [34]. Renal impairment and P-gp 
inhibition are the major independent risk factors for increased dabigatran exposure 
and increased risk of bleeding. Hence, renal function assessment at baseline and 
periodically thereafter is recommended. Dose adjustments for dabigatran doses in 
patients with severe renal impairment (CrCl 30 mL/min or less) are recommended. 
Caution must be used in the elderly, as the risk of stroke and bleeding increases 
with age, as seen in an analysis of the RE-LY (Randomized Evaluation of Long-Term 
Anticoagulant Therapy) trial [35]. Dabigatran is contraindicated for use in patients 
with mechanical heart valves. The RE-ALIGN (Randomized, Phase II Study to 
Evaluate the sAfety and Pharmacokinetics of oraL dabIGatran Etexilate in Patients 
after Heart Valve replacement) trial was terminated early due to thromboembolic 
events (valve thrombosis, stroke, and myocardial infarction), and major bleeding 
was observed in the dabigatran group compared to the warfarin group in heart valve 
patients [36].
Besides major and minor bleeding, gastrointestinal adverse effects have been 
reported in studies at an incidence rate ranging from 24.7 to 35% [34]. The gas-
trointestinal adverse effects reported include but are not limited to dyspepsia, 
gastritis, abdominal pain or discomfort, and epigastric discomfort [34]. Due to the 
prevalence of these adverse effects, it is necessary to educate the patient about the 
potential side effects and advise them not to abruptly discontinue the medication 
before notifying their healthcare provider [34].
One distinguishing feature of dabigatran is the increase in bioavailability by 75% 
that occurs if the capsule is broken, chewed, or emptied out of the capsule shell [34]. 
Pulmonary Embolism
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This leads to an increased risk of toxicity, such as major bleeds [34]. Since the capsule 
cannot be manipulated due to the stated reason, the medication should not be admin-
istered via a feeding tube of any type [34]. The medication must be kept in its original 
container. It must be discarded after 4 months from the date the package was opened 
due to the lack of stability with light or humidity exposure that may lead to product 
breakdown and potency loss [34].
There is a specific reversal agent approved for dabigatran. The agent named 
idarucizumab (Praxbind®) is a monoclonal antibody with 350 times more affinity 
for dabigatran than thrombin [15, 51]. Diuresis may also help with the excretion of 
dabigatran as well [34].
6.4 Edoxaban
Edoxaban is an oral direct factor-X inhibitor approved in the United States for 
the treatment of PE. Approval was based primarily on the Hokusai VTE study, 
which evaluated 3319 patients with PE. The trial showed that edoxaban was not 
inferior to warfarin but had a lower bleeding risk [37]. Dosing and special consider-
ations for edoxaban use for PE treatment are discussed in Table 1. The oral bioavail-
ability is approximately 60%, and renal elimination accounts for approximately 
50% of unchanged drug. Edoxaban’s terminal half-life ranges between 10 and 14 h. 
Interestingly, edoxaban blood levels are lower in patients with better renal function 
averaging about 40% less in patients with CrCL >95 mL/min when compared to 
those with CrCl >50 to ≤80 mL/min [38]. Bleeding complications such as hemor-
rhage (major or minor) appear to be the most common adverse effects associated 
with edoxaban use [38, 39]. Lastly, andexanet alfa (Andexxa®) can also be used to 
reverse edoxaban (off-label) in life-threatening or uncontrollable bleeding [58].
7. Thrombolytic therapy
Thrombolytic therapy for PE may be administered systemically or directed 
by a catheter into the pulmonary arteries to accelerate the resolution of acute PE. 
Thrombolytic therapy can lower pulmonary artery pressure and increase arterial 
oxygenation [22]. Studies limiting thrombotic therapy in acute PE have shown the 
best outcomes by restricting it to patients presenting with a massive (high-risk) 
PE [22, 59]. Patients presenting with hemodynamic instability, right ventricular 
dysfunction, and without significant risk of bleeding are considered potential 
candidates for emergency thrombolytic therapy [4, 60]. The results from timely 
administration of thrombolytic therapy may be seen within 36 h [61]. Mortality 
rates occur in up to 30% of patients categorized as high risk and make the timing 
of therapeutic intervention critical [62–64]. Adverse events, especially the high 
incidence of bleeding and hemorrhagic stroke, require careful consideration prior 
to starting thrombolytic therapy [65, 66]. Systemic alteplase (Activase®) is the 
only FDA-approved thrombolytic for the management of acute massive (high risk) 
hemodynamically unstable PE [67]. All anticoagulants must be stopped prior to the 
initiation of alteplase and 100 mg IV infused over 2 h is the most common regimen. 
Alternative weight-based regimens for patients weighing <65 kg may be considered 
[68]. A weight-based regimen with a 15 mg bolus followed by 0.75 mg/kg over 
30 min (max 50 mg) and then 0.5 mg/kg over the next 30 min (max 35 mg) have 
shown efficacy without increased bleeding [68]. Intra-catheter-directed alteplase 
0.5–2 mg/h for 2–15 h for a total dose of 4–24 mg has been used successfully in 
facilities by experienced physicians and well-designed protocols, but this route of 
administration is not FDA approved [69]. Tenecteplase (TNKase®) and reteplase 
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(Retavase®) have been used for acute massive (high risk) PE, but are not FDA 
approved for use in patients with PE [70, 71].
8. Monitoring parameters for anticoagulation therapy
Therapeutic anticoagulation is the gold standard for the management of VTE. 
The narrow therapeutic efficacy window creates challenges in drug selection and 
monitoring to deliver the appropriate dose to prevent further embolic events while 
not causing a life-threatening bleed. Historically, guidelines in VTE management 
include the option of continuous UFH; however, LMWH and direct factor Xa inhibi-
tors have begun to displace UFH as first-line agents [1, 5, 34]. Traditionally, aPTT 
has served as the marker of therapeutic anticoagulation in patients with VTE due to 
the exclusive use of UFH [40–47]. Despite decades of experience with aPTT values, 
challenges in the precision monitoring of anticoagulation continue to create thera-
peutic dilemmas for clinicians [41, 42]. The lack of standardized methods in moni-
toring and individualized patient factors, including biological variables and heparin 
resistance, are credited as most problematic when using aPTT to measure the effect 
of UFH [43, 44]. While aPTT values remain the standard for measuring the effects 
of UFH, anti-factor Xa (anti-Xa) heparin assay (HA) is recommended as a monitor-
ing option in place of aPTT values by the American College of Chest Physicians 
(ACCP) and the College of American Pathologists (CAP) [34, 39]. Anti-Xa levels 
demonstrate greater consistency in measuring anticoagulation, since they are based 
on the functional activity of all heparins [46, 47]. Comparatively, the aPTT test mea-
sures the function of the intrinsic and common pathways of the coagulation cascade, 
which can have significant variability among individuals [38, 42, 43].
The implementation of heparin dosing protocols has improved the uniformity of 
therapeutic anticoagulation with UFH. Most of these protocols are “weight-based,” 
and changes in the units of UFH per hour are adjusted based on the aPTT values 
[50]. This method of dosing UFH has led to concerns regarding both “over” and 
“under” anticoagulation using aPTT-level directed therapy. Combining aPTT and 
anti-Xa levels has been proposed as a method to overcome the variable swings com-
monly seen in patients with multiple comorbidities, obesity, older age (>70 years), 
16 drug-induced coagulopathies, pharmacokinetic changes, and preexisting genetic 
alterations [37, 38, 40, 42, 45–47]. Some hospital systems have transitioned from 
the use of aPTT to anti-Xa HA altogether and are reporting the faster attainment 
of therapeutic anticoagulation in addition to the elimination of multiple laboratory 
tests and dosage changes [46].
Based on numerous studies, anti-Xa levels have been shown to be a viable 
alternative to aPTT to achieve and maintain therapeutic anticoagulant levels with 
UFH [36, 40, 43, 48–50]. Anti-Xa levels have provided a more consistent method of 
monitoring a patient’s response to UFH and demonstrate fewer blood samples and 
dosage adjustments compared to aPTT values [42, 47].
INR monitoring is recommended more frequently upon warfarin initiation 
(once a day) and can be extended to typically once a month once INR is stable and 
in a therapeutic range [25].
Routine laboratory monitoring is not indicated for DOAC, but anti-factor Xa (FXa) 
can be useful for excluding clinically important levels of DOAC [53]. Edoxaban may 
elevate the PT and aPTT, but FXa activity may be a better measure of effectiveness [39]. 
Fondaparinux does not require laboratory monitoring as well. Anti-factor Xa activity is 
probably the assay for monitoring fondaparinux but is not usually obtained in real time 
[54]. For the qualitative assessment of dabigatran, thrombin time (TT) and aPTT may 





Anticoagulant dosing of obese patients with PE remains to be an area that has 
not been well studied [72]. The bulk of the data comes from pharmacokinetic/
pharmacodynamic (PK/PD) studies and subgroup analyses of premarketing 
trials comparing obese patients to patients with normal body weight [52–54, 72]. 
Furthermore, warfarin appears to have the most robust data available in this 
population. Warfarin pharmacokinetics have been compared in various studies of 
obese patients with a BMI > 30 and 40 kg/m2 to normal body weight subjects. These 
studies found that obesity was associated with a greater delay and dosage to achieve 
a therapeutic INR. Data associated with the risk of bleeding, however, have been 
conflicting, indicating that obesity may or may not increase the risk [72]. While 
warfarin has the most robust data in this population, the usage of warfarin appears 
to be on the decline [72].
Dabigatran is a direct thrombin inhibitor that sets it apart from other DOACs. 
Subgroup analyses of Phase 3 trials for VTE (RE-LY) and atrial fibrillation 
(RECOVER) suggested no significant differences in the efficacy and safety out-
comes of obese patients in comparison with those with lower body weights [53, 54]. 
In contrast, treatment failures have been documented in morbidly obese patients 
using standard doses. The authors reported that standard doses failed to achieve 
“therapeutic levels,” suggesting a higher volume of distribution (Vd) and a higher 
clearance [55, 56].
The factor X inhibitors, rivaroxaban, apixaban, and edoxaban also have some 
data in obese populations. Rivaroxaban was evaluated in a small PK/PD study 
involving a heterogeneous group of subjects including those in the obese range 
(>120 kg). The half-life, Vd, and clearance declined slightly with increasing body 
weight. The authors felt the declines were not clinically relevant [57]. A separate 
PK/PD analysis using pooled data from the phase ll EINSTEIN DVT and ODIXa-
DVT trials reported similar findings. These studies enrolled some patients with 
BMIs >35 kg/m2 and found clinical benefits comparable across all weight groups 
[58]. The authors of this analysis also concluded that standard doses should be suf-
ficient to treat obese patients; however, a review questioned whether the data were 
robust enough to draw that conclusion [52, 58].
In the apixaban’s phase 1 PK/PD study, the pharmacokinetic data were somewhat 
different compared to those for rivaroxaban. The overall Vd was higher in subjects 
>120 kg or BMI > 30 kg/m2 than normal body weight subjects. The half-life declined 
almost proportionately to the increase in Vd (27% ↓ vs. 24% ↑ for half-life and Vd, 
respectively). Peak level and area under the plasma drug concentration-time curve 
(AUC) were also reduced in the higher body weight subjects. The authors concluded 
the differences were unlikely to be of clinical significance [59]. The phase 3 trials, 
ARISTOTLE and AMPLIFY, contained a significant proportion of patients with 
body weights >100 kg and BMIs above 30 kg/m2. Subgroup analyses found no differ-
ences in efficacy; however, more bleeding episodes were reported in the ARISTOTLE 
trial. Whether the increase in hemorrhagic complications between these trials was 
due to age, renal clearance, or other patient-specific factors is unclear [60–62].
Edoxaban has less data than other DOACs. Phase 3 Hokusai-VTE enrolled a large 
group of patients >100 kg. There was no difference in efficacy and safety compared 
to groups with other weights [63].
A recent international retrospective study of LMWHs examined dosing in 
obesity regarding capped (<18,000 IU/d) and uncapped dosages (>18,000 IU/d). 
The data were obtained from the RIETE Registry, a large prospective case series of 
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patients with VTE. LMWHs included enoxaparin, dalteparin, and tinzaparin. The 
authors reported that the results may be subject to selection bias despite attempts 
to control for potential confounders in multivariable analysis. Nevertheless, they 
found that after adjustment for multiple potential confounders, patients with 
obesity (>100 kg or BMI >30 kg/m2) who received capped doses were at a lower risk 
of having the composite outcome of VTE recurrences, major bleeding, or all-cause 
death at 15 and 90 days. Bleeding was also reduced with capped dosages [64].
A recent retrospective study of UFH for acute venous thromboembolism (VTE) 
compared three body mass index (BMI) cohorts: (i) non-obese (less than 30 kg/m2),  
(ii) obese (30 to 39.9 kg/m2), and (iii) morbid obesity (⩾40 kg/m2). The dosing 
employed was based on actual body weight. The median times to therapeutic aPTT 
were reported as 16.4, 16.6, and 17.1 h in each of the three cohorts [65].
Obese patients on warfarin may require a higher dose or more time to achieve a 
therapeutic INR. Bleeding risk may or may not be greater. Available data for DOACs 
other than dabigatran suggested usual doses may not negatively impact efficacy 
in obese patients. Apixaban studies reported conflicting results on bleeding risk. 
However, there are probably insufficient data for DOACs to suggest that usual doses 
would be adequate in the subgroup of morbidly obese patients. Obese patients 
with capped doses of LMWHs may have better efficacy and safety outcomes. 
Capped dosages are conditionally recommended in the 2018 American Society of 
Hematology guidelines [66].
9.2 Renal dysfunction
Anticoagulants have been evaluated in CKD and ESKD patients in various PK/PD  
and clinical efficacy trials [67]. The PK/PD of warfarin in CKD and ESKD is 
not completely understood [67, 68]. Official dosing guidelines do not recommend 
an alteration of dose [67]. Warfarin is extensively metabolized by the cytochrome 
P450 type 2C9 (CYP2C9) enzyme [84]. Although not removed by dialysis, there are 
no data evaluating whether this procedure alters its pharmacokinetics and pharma-
codynamics [67]. One study comparing individuals with a GFR of 30–59 mL/min 
and healthy controls reported a shorter half-life and increased clearance. Other data 
showed that CKD, especially GFRs <30 mL/min per 1.73 m2 or ESKD, complicates 
warfarin therapy [70, 71]. These data reported that lower doses were required to 
maintain therapeutic INR with greater fluctuations in INR values and higher risks 
of major bleeding events for any given INR value. A recent meta-analysis of ESKD 
patients with atrial fibrillation found that warfarin had no benefit in reducing 
ischemic stroke incidence. The authors concluded that the drug appeared to be asso-
ciated with a significantly higher risk of hemorrhagic stroke but no increased risk of 
other types of major bleeding. They also found no change in mortality [72, 73]. How 
all these data apply to other indications such as PE is unknown.
The various DOACS have also been evaluated in renal disease. A small study of 
dabigatran using reduced doses (150 mg daily for CKD and 50 mg daily for ESKD) 
examined the effect of CKD and ESKD on pharmacokinetic parameters. Subjects 
with a creatinine clearance <30 mL/min demonstrated a 6.5-time increase in the 
AUC with a doubling of the half-life compared to normal controls [74].
Rivaroxaban has somewhat conflicting data in CKD and ESKD. In a phase 3 trial 
subgroup analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition 
Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism 
Trial in Atrial Fibrillation (ROCKET AF), the authors reported that reduced renal 
function (creatinine clearances <80 mL/min) had no impact on rivaroxaban’s 
effectiveness and safety [75]. In contrast, a PK/PD study comparing dialysis 
patients to normal controls reported a 56% increase in AUC when 15 mg doses 
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were administered after dialysis [90]. The AUC was decreased by only 5% when 
administered pre-dialysis suggesting dialysis is ineffective in clearing the drug [90]. 
Another PK/PD study comparing three ranges of renal insufficiency to normal con-
trols reported AUCs of 1.4-, 1.5-, and 1.6-fold higher in cases of creatinine clearance 
concentrations of 50–80, 30–50, and < 30 mL/min, respectively [76].
Pharmacokinetic data for apixaban appear similar to those of rivaroxaban, 
except that the incremental upsurges in AUC are somewhat lower in magnitude. A 
small PK/PD study using a 5 mg dose in ESKD patients and normal controls found 
a 36% increase in AUC in the ESKD group compared to controls. The apixaban dose 
was administered pre-dialysis [77]. Another small PK/PD study used a single 10 mg 
dose and compared subjects with varying degrees of CKD to normal controls [13]. 
Compare to the controls, the AUCs increased by 16%, 29%, and 38% in the CKD 
cohorts with creatinine clearances of 50–80, 30–50, and < 30 mL/min, respectively. 
The mean half-life was only slightly increased in the total CKD population (17 h) 
compared to the controls (15 h) [77]. The overall results for both studies were not 
unexpected, as apixaban is metabolized more extensively and demonstrates less 
unchanged renal elimination than other DOACs [1]. Again, the drug appears to be 
poorly dialyzable [67].
Edoxaban was evaluated in a small PK/PD study comparing CKD subjects to 
normal controls. The data, available as an abstract only, showed that the mean 
AUCs increased by 32%, 74%, and 72% with creatinine clearances of 50–80, 30–50, 
and < 30 mL/min (not on dialysis), respectively [67]. The mean AUC for subjects 
on peritoneal dialysis was 93% [67]. Similar to other Factor Xa inhibitors, edoxaban 
is poorly cleared by hemodialysis [78].
Probably, the best data for LMWH come from a subgroup analysis of the 
ExTRACT TIMI 25 trial. This study compared a 1 mg/kg per day dose of enoxaparin 
to UFH in ST-elevation myocardial infarction (STEMI) patients with CrCLs less 
than 30 mL. There was no significant difference in mortality or recurrent MI (33 
vs. 37.7%) and in bleeding risk (5.7 vs. 2.8%) for enoxaparin and UFH, respectively. 
Mortality increased for both drugs as renal function declined [94].
UFH is rapidly eliminated by the reticular endothelial system and, to a lesser 
extent, the kidney. However, the degree to which the RES functions in this role 
varies from person to person. Nevertheless, lower doses in VTE treatment are 
recommended to reduce bleeding risk. An advantage for UFH over enoxaparin is the 
ability to reverse the former easier with protamine [16, 79].
All DOACs increase AUC with the magnitude inversely proportional to renal 
function. These drugs may be the anticoagulants of choice for stages 1, 2, and 3 
CKD [95]. Some sources recommend apixaban as an alternative to warfarin in 
selected patients with ESKD [67]. Warfarin, although predominately metabolized 
in the liver, may require a lower dose to reach a therapeutic INR. Historically, it is 
the oral anticoagulant of choice in ESKD [16, 79]. However, how does warfarin’s 
potential lack of benefit in ESKD patients with AF apply to PE? Are LMWHs better 
than UFH? Both were associated with similar mortality increases in STEMI patients 
with declining kidney function. Should these data also apply to renal failure 
patients and PE?
9.3 Liver dysfunction
Patients with cirrhosis typically have elevated INR and aPTT. As a result, there 
have been misconceptions that these patients are “autoanticoagulated.” However, 
patients with liver disease may have a substantially increased risk of VTE (RR 
1.74 (95% CI, 1.54–1.95) for liver cirrhosis and 1.87 (95% CI, 1.73–2.03) for non-
cirrhotic liver disease) [95]. A meta-analysis in patients with the liver disease found 
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the incidence of PE from nine studies to be 0.28% (95% CI 0.13–0.49%) and the 
prevalence of PE from two studies to be 0.36% (95% CI 0.13–0.7%) [96].
Determining the ideal anticoagulant to use after a PE in a patient with liver 
cirrhosis may be challenging. Warfarin can be safely used in patients with liver 
dysfunction. Elevations in baseline INR due to liver disease, however, may lead to 
unclear INR targets during warfarin therapy [80, 81]. LMWHs have a good safety 
profile with liver dysfunction; however, subcutaneous administration may limit 
compliance, and lower anti-Xa levels in liver dysfunction limit efficacy monitor-
ing [82, 83]. Finally, there are a lack of data on using DOACs in patients with liver 
disease. Clinical trials with DOACs excluded patients with liver disease as most 
DOACs are predominantly cleared hepatically (apixaban 75%, rivaroxaban 65%, 
edoxaban 50%, and dabigatran 20%) [84, 85]. Therefore, dosing recommendations 
are derived from pharmacokinetic studies (Table 3).
Regardless of which anticoagulant is chosen, the risk of bleeding should be 
thoroughly evaluated. In patients with liver disease, bleeding can be due to varices, 
portal hypertensive gastropathy, peptic ulcer disease, and arteriovenous malforma-
tions. A small, 45-patient cohort study, comparing DOACs to warfarin/LMWH 
found no difference in thrombotic events. Still, there were significantly fewer 
major bleeding episodes in the DOAC group (1 patient [4%] vs. 5 patients [28%], 
p = 0.03) [86].
9.4 Cancer patients
Cancer patients have a five- to sevenfold increased risk for VTE within the first 
year of diagnosis [101]. Additionally, VTE is considered an independent predictor 
of mortality in these patients [87, 88]. The pathophysiological and epidemiologi-
cal association between PE and cancer is well established. For decades, LMWHs 
were considered a first-line therapy for cancer-associated PEs, as knowledge of the 
efficacy and safety of DOACs in cancer patients was lacking [89–91]. Since then, 
four large randomized control trials have been published comparing DOACs with 
LMWH that have highlighted the utilization of most DOACs for the treatment of 
PEs [90, 92–94].
The Hokusai VTE Cancer trial randomized 1050 cancer patients with acute VTE 
to either edoxaban, an oral direct factor Xa inhibitor, or dalteparin, an LMWH. The 
trial found that edoxaban was non-inferior to dalteparin for the primary outcome 
of recurrent VTE or major bleeding during a follow-up period of 12 months (95% 
confidence interval 0.70 to 1.36; p = 0.006) [107]. There was a lower rate of VTE, 







Apixaban No dosage adjustment. Use with caution.
No dosage adjustments 
provided.
Use is not recommended.
Rivaroxaban No dosage adjustment. Avoid use. Avoid use.
Edoxaban No dosage adjustment. Use is not recommended. Use is not recommended.
Dabigatran No dosage adjustment. Use with caution.
No dosage adjustments 
provided.
No dosage adjustments 
provided.
Table 3. 
FDA recommendations of DOACs in liver dysfunction.
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rate was significantly higher (risk difference of 2.9 (0.1 to 5.6)) [107]. A nonsignifi-
cant lower VTE rate was seen, but the major bleeding rate was significantly higher 
in the edoxaban group. Major bleeding events were frequently observed in the 
subgroup with upper gastrointestinal tract neoplasms [107].
SELECT-D randomized 406 patients with cancer and acute VTE to oral rivaroxa-
ban, a factor, or dalteparin for a treatment duration of 6 months [108]. SELECT-D 
was a 6-month open-label, pilot, randomized control study that compared rivar-
oxaban 15 mg BID for 3 weeks then 20 mg once daily to dalteparin (200 IU/kg once 
daily for 1 month, then 150 IU/kg once daily) in patients with VTE and solid or 
hematologic cancers [108]. The trial found that the VTE recurrence rate was 4% 
with rivaroxaban and 11% with dalteparin (HR 0.43, 95% CI 0.19 to 0.99) [108]. 
Major bleeding occurred in 4% with dalteparin and 6% with rivaroxaban (HR 1.83, 
95% CI 0.68 to 4.96) and clinically relevant, nonmajor bleeding occurred in 4% 
with dalteparin and 13% with rivaroxaban (HR 3.76, 95% 1.63 to 8.69) [108].
CARAVAGGIO was an open-label, non-inferior study that randomized 1170 
patients to apixaban (10 mg twice daily for 7 days, then 5 mg twice daily) or dalte-
parin (200 IU/kg once daily for 1 month, then 150 IU/kg once daily) for 6 months 
of treatment [109]. The trial resulted in a VTE recurrence rate of 5.6% with apixa-
ban and 7.9% with dalteparin (risk difference − 2.3%; HR 0.63, 95% CI 0.37 to 1.07, 
p < 0.001) [109]. Additionally, major bleeding occurred in 3.8% in the apixaban 
group versus 4% in the dalteparin group (risk difference − 0.2%; HR 0.82, 95% CI 
0.4 to 1.69, p = 0.60) [109].
Given that these oral agents have shown efficacy and provide a more convenient 
medication dosage form, we have already begun to see a shift in the way PEs are 
treated in cancer patients [90, 92–94]. However, since many of these studies have 
excluded patients with GI tumors or a history of GI bleeding, it is still recommended 
to continue using LMWH in these patients due to the higher GI bleeding risk seen 
with DOACs. [90, 92–94]. If a DOAC is to be utilized, the choice of which oral anti-
coagulant to be used in a cancer patient should be made on an individual basis with 
considerations of drug interactions with chemotherapy agents and the type of cancer.
9.5 Pregnancy
UFH and LMWH remain the only currently available choices for the safe man-
agement of VTE including PE during pregnancy and puerperium. UFH provides 
the least exposure to the fetus and risk to the mother, since it does not cross the 
placenta, is not distributed into breast milk, and the dose is easily titrated [110]. 
LMWHs have a similar safety profile as UFH for the fetus since they also do not 
cross the placenta. Concerns about distribution into breast milk have been raised 
[110, 111]. Most studies have not demonstrated that the LMWH levels in breast milk 
are high enough to cause coagulopathy when using standard prophylaxis doses. 
Further studies are needed for a complete safety profile.
The ability to easily monitor aPPT levels for UFH and anti-Xa levels for LMWHs 
provides clinicians with the ability to maintain therapeutic concentrations through-
out pregnancy. Therapeutic-level monitoring provides safety and efficacy for 
both the fetus and the mother, since changes in the drug volume of distribution 
and clearance progressively increase throughout pregnancy [22, 110, 112–114]. 
Additionally, UFH and LMWH have short half-lives, allowing for anticoagulation 
to be maintained within 24 h of delivery and permitting the safe use of neuroaxial 
anesthesia if needed [111, 115]. Restarting LMWH within 6 h postdelivery in 
patients without bleeding concerns has been shown to be safe. Anticoagulation 
should be maintained during puerperium [110]. Thromboprophylaxis for future 
pregnancies with UFH or LMWH is recommended for women at risk [116, 117].
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The safety profile and pharmacokinetics of DOACs currently do not favor their 
use during pregnancy or puerperium, since they cross the placenta and distribute into 
breast milk [110, 118]. The use of DOACs may be considered in women who are not 
or are no longer breastfeeding. The inability to readily monitor DOAC levels limits the 
clinician’s ability to maintain therapeutic levels throughout pregnancy and puerperium 
due to the pharmacokinetic changes listed above. Maintaining a safe and therapeutic 
efficacious anticoagulation regimen up to and through the time of delivery requires a 
multidisciplinary effort and needs to be closely coordinated [110, 111, 115].
9.6 Elderly
The risk of thromboembolic disease, including PE, increases with age [119–121].  
The trauma to the vascular endothelium caused by a thromboembolic event  
places the patient at a higher risk of recurrence, requiring prolonged anticoagula-
tion [119, 122]. Comorbidities accompanying aging, especially cardiovascular and 
pulmonary disease, add to the complexity of treatment of thromboembolic disease 
[123]. The increased risk for bleeding further complicates the safe management of 
an acute venous thromboembolic event, and prolonged anticoagulation is required 
to prevent future events [4].
PE in elderly patients may not present with the typical symptoms seen in 
younger patients, making early diagnosis more challenging in this population. 
Several studies have found syncope to be the most frequent presenting symptom in 
elderly patients, versus pleuritic chest pain in a younger population [124–126]. Early 
pharmacotherapy intervention is critical to prevent further thrombus formation, 
regardless of the patient’s age [119].
Recommendations for initial treatment for PE in a stable patient regardless of 
the prognosis include DOACs (apixaban or rivaroxaban) or initial LMWH, followed 
with dabigatran or edoxaban. LMWH or UFH and warfarin may be preferred in 
patients with reduced renal function (CrCL <30 mL/min) [127].
Stable patients with a good prognosis may be managed in an outpatient setting. 
The current recommendations for stable patients with a poor prognosis require 
hospitalization [127]. A thorough medication history is important prior to starting a 
DOAC due to the potential drug–drug interactions seen with this class of anticoagu-
lants. P-glycoprotein inhibitors or CYP3A4 inhibitors or inducers should be avoided, 
since they can alter the plasma of DOACs [127]. The unstable patient requires hospi-
talization and may be a candidate for thrombolytic therapy, preferably by catheter-
directed thrombolysis [127].
9.7 COVID-19 patients
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) from Wuhan, Hubei province, China, in December 2019 has adversely 
impacted the world. Among the several complications related to SARS-CoV-2 is VTE 
[128], a systematic review of 3487 COVID-19 patients from 30 studies demonstrated 
VTE incidence to be 26%, 12% for PE with or without DVT, and 14% for DVT alone.
The etiology of PE in COVID-19 is secondary to the well-known VTE risk fac-
tors, with indirect aspects of the severity of illness and direct effects of SARS-CoV2 
viral infection. These patients are at VTE risk due to the recurrent use of intravascu-
lar access devices, sedation, and vasopressors, within the intensive care unit (ICU) 
setting. These factors promote stasis. Respiratory failure, hypoxia, comorbidi-
ties, multi-organ failure, obesity, and prolonged immobility are other elements. 
Additional confounding factors include a history of VTE and or neoplasm, sepsis, 
surgery, trauma, or stroke [97, 98].
Pulmonary Embolism
16
COVID-19 is associated with a profound early response of proinflammatory 
cytokines. This may result in a cytokine storm, increased risk of vascular hyperper-
meability, multi-organ failure, and death [129, 130]. While thrombin’s primary role 
is to accelerate clot formation via platelet activation and the conversion of fibrinogen 
to fibrin, thrombin equally exerts multiple cellular effects. It could further enhance 
inflammation through proteinase-activated receptors (PARs). Thrombin production 
is highly regulated via negative feedback mechanisms and physiological antico-
agulants, such as the protein C system, antithrombin III, and tissue factor pathway 
inhibitor [131]. These three control mechanisms may become impaired throughout 
the inflammatory process, resulting in decreased anticoagulant concentrations 
secondary to reduced production and increased consumption. This impaired proco-
agulant–anticoagulant equilibrium results in disseminated intravascular coagulation 
(DIC), microthrombosis, multi-organ failure, and elevated d-dimer levels [99–101]. 
Hypercoagulable state, endothelial dysfunction, injury, and viral-induced procoagu-
lant effect all also play an immense role in COVID-19-associated PE [102–104].
Both LMWH and UFH are recommended for VTE prophylaxis and PE treatment in 
COVID-19 patients. The recommended dose of the LMWH enoxaparin for VTE pro-
phylaxis is 40 mg (4000 IU) daily. An intermediate dose of LMWH enoxaparin 40 mg 
subcutaneously every 12 h is recommended in the critically ill, the obese, and those 
patients with multiple VTE risk factors. A UFH dose of 5000 IU Q8H is recommended 
for VTE prophylaxis, and doses of up to 7500 IU have been employed in critically ill 
patients [105–109]. DOACs are recommended in stable patients and in the post-acute 
phase of PE and outpatient settings when the benefits from their use outweigh the 
risks. Renal function monitoring with dosage modifications is recommended when 
LMWH, UFH, and DOACs are employed. Additionally, Anti-Xa monitoring is recom-
mended in patients requiring the therapeutic anticoagulation with LMWH, UFH, 
and DOAC therapy. DOAC plasma level monitoring is also recommended [106, 110]. 
Therapeutic anticoagulation should always be considered first; thrombolytic therapy 
is recommended in patients who go to develop sub-massive or massive PE. An inferior 
vena cava filter may be employed in at-risk patients; extracorporeal membrane oxy-
genator (ECMO) is an option, in conjunction with surgical embolectomy or catheter-
directed management [1, 111, 112]. Several weeks of therapy is recommended with 
LMWH or DOACs, post-hospitalization for COVID-19 patients [132].
10. Conclusions
PE is a medical emergency that affects thousands of Americans each year. 
Thousands of Americans die from this condition annually. The therapy for PE has 
evolved over the years. Traditional therapies such as UFH, VKA, and warfarin are 
being abandoned by clinicians in favor of LMWH and DOACs. Reversal agents such 
as 4-factor prothrombin complex concentrate, andaxanet alfa, and the monoclo-
nal antibody idarucizumab have allowed clinicians to push the boundaries of PE 
management with confidence, particularly in the outpatient setting. Special popula-
tions, such as obese, renal dysfunction, liver impairment, cancer, pregnancy, and 
COVID-19 patients with PE, pose a tremendous therapeutic burden and challenge to 
clinicians. Despite these challenges, tremendous progress has been made, with dem-
onstrated improved patient outcomes in PE treatment over the last three decades.
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